Direkt zum Inhalt
Merck
  • The Structural Basis of Functional Improvement in Response to Human Umbilical Cord Blood Stem Cell Transplantation in Hearts With Postinfarct LV Remodeling.

The Structural Basis of Functional Improvement in Response to Human Umbilical Cord Blood Stem Cell Transplantation in Hearts With Postinfarct LV Remodeling.

Cell transplantation (2013-12-18)
Yong Chen, Lei Ye, Jia Zhong, Xin Li, Chen Yan, Margaret P Chandler, Steve Calvin, Feng Xiao, Mesfin Negia, Walter C Low, Jianyi Zhang, Xin Yu
ZUSAMMENFASSUNG

Cellular therapy for myocardial repair has been one of the most intensely investigated interventional strategies for acute myocardial infarction. Although the therapeutic potential of stem cells has been demonstrated in various studies, the underlying mechanisms for such improvements are poorly understood. In the present study, we investigated the long-term effects of stem cell therapy on both myocardial fiber organization and regional contractile function using a rat model of postinfarct remodeling. Human nonhematopoietic umbilical cord blood stem cells (nh-UCBSCs) were administered via tail vein to rats 2 days after infarct surgery. Animals were maintained without immunosuppressive therapy. In vivo and ex vivo MR imaging was performed on infarct hearts 10 months after cell transplantation. Compared to the age-matched rats exposed to the identical surgery, both global and regional cardiac functions of the nh-UCBSC-treated hearts, such as ejection fraction, ventricular strain, and torsion, were significantly improved. More importantly, the treated hearts exhibited preserved fiber orientation and water diffusivities that were similar to those in sham-operated control hearts. These data provide the first evidence that nh-UCBSC treatment may prevent/delay untoward structural remodeling in postinfarct hearts, which supports the improved LV function observed in vivo in the absence of immunosuppression, suggesting a beneficial paracrine effect occurred with the cellular therapy.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Natriumchlorid, Molecular Biology, DNase, RNase, and protease, none detected, ≥99% (titration)
Sigma-Aldrich
Natriumchlorid -Lösung, 5 M in H2O, BioReagent, Molecular Biology, suitable for cell culture
Sigma-Aldrich
Natriumchlorid, BioXtra, ≥99.5% (AT)
Sigma-Aldrich
Natriumchlorid, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture, ≥99%
Sigma-Aldrich
Natriumchlorid -Lösung, 0.9% in water, BioXtra, suitable for cell culture
Sigma-Aldrich
hEGF, EGF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Natriumchlorid -Lösung, 5 M
SAFC
Natriumchlorid -Lösung, 5 M
Sigma-Aldrich
Natriumchlorid, BioUltra, Molecular Biology, ≥99.5% (AT)
Sigma-Aldrich
EGF human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
Natriumchlorid, meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%
Sigma-Aldrich
Natriumchlorid -Lösung, BioUltra, Molecular Biology, ~5 M in H2O
Sigma-Aldrich
Natriumchlorid, 99.999% trace metals basis
Sigma-Aldrich
Epidermaler Wachstumsfaktor human, EGF, recombinant, expressed in Escherichia coli, >97% (SDS-PAGE)
Sigma-Aldrich
Natriumchlorid, BioPerformance Certified, ≥99% (titration), suitable for insect cell culture, suitable for plant cell culture
Sigma-Aldrich
Natriumchlorid -Lösung, 0.85%
Sigma-Aldrich
Natriumchlorid-35Cl, 99 atom % 35Cl
Sigma-Aldrich
Natriumchlorid, tablet
Sigma-Aldrich
Natriumchlorid, random crystals, 99.9% trace metals basis
Sigma-Aldrich
2-Phenylindol, technical grade, 95%
Sigma-Aldrich
Natriumchlorid, AnhydroBeads, −10 mesh, 99.999% trace metals basis
Sigma-Aldrich
FGF-2 human, recombinant, expressed in insect cells, ≥85% (SDS-PAGE)